Intrinsic resistance due to beta-lactamase production
Failure to respond is a key diagnostic clue
Most macrolides (azithromycin, clarithromycin)
Insufficient clinical data for routine use
Not recommended by CDC 2025 guidance
Anti-tuberculosis agents
Not effective against F. tularensis
Exclude TB overlap if biopsy shows caseating granulomas
Surgical management
Lymph node drainage indications
Suppurative lymphadenitis with abscess
Surgical drainage or excision required in approximately 23% of patients
Fluctuant nodes confirmed by ultrasound or CT
Retropharyngeal abscess
Incision and drainage via transoral or external approach
ENT or head and neck surgery required
Conglomerate lymphadenopathy with necrosis
Drainage plus continued antibiotic therapy
Antibiotic therapy continues for minimum 10 days post-drainage
Post-exposure prophylaxis
Bioterrorism exposure scenario
Ciprofloxacin 500 mg PO BID for 14 days
Started within 24 hours of confirmed exposure
Doxycycline 100 mg PO BID for 14 days
Alternative to ciprofloxacin
Per 2025 CDC MMWR recommendations for bioterrorism response
Special Populations
Pregnancy
Antibiotic selection in pregnancy
Fluoroquinolones (relative avoidance)
Potential cartilage toxicity in fetal animal models
Used when benefits outweigh risks in severe disease
Doxycycline (avoid especially after 15 weeks)
Fetal bone and tooth staining
Avoid after mid-second trimester
Gentamicin (preferred for severe disease in pregnancy)
5 mg/kg IV once daily with fetal monitoring
Renal and audiologic monitoring in mother
Risk of fetal eighth nerve toxicity with prolonged use
Maternal management considerations
Hydration and fever control
Fever above 38.5 C associated with fetal risk
Acetaminophen preferred for antipyresis
Fetal monitoring
Continuous electronic fetal monitoring if gestational age viable
Obstetric consultation for all pregnant patients
Imaging approach
Neck ultrasound preferred to avoid radiation
CT neck only when airway assessment critical and benefits outweigh risks
Geriatric
Atypical presentation features
Blunted fever response
Temperature below 38 C may still represent significant infection
Afebrile presentation possible in frail older adults
Delirium as presenting symptom
Confusion without prominent pharyngitis
Broader infectious workup required
Medication considerations
Aminoglycoside nephrotoxicity risk
Baseline creatinine and GFR before initiation
Dose reduction for GFR below 50 mL/min
Extend interval to every 36 to 48 hours
Fluoroquinolone risks in older adults
QT prolongation on baseline ECG
Tendon rupture risk especially with concurrent steroids
Doxycycline
Photosensitivity and esophageal irritation
Take with full glass of water and remain upright
Disposition tendency
Lower threshold for admission in frailty
Limited physiologic reserve
Social isolation and inability to monitor at home
Pediatrics
Pediatric antibiotic dosing
Gentamicin IV or IM
2.5 mg/kg IV or IM every 8 hours (TID) for minimum 10 days
Renal function and levels monitoring
Ciprofloxacin
15 mg/kg IV or PO BID (maximum 500 mg per dose)
10 to 14 days duration
Streptomycin IM
15 mg/kg IM BID (maximum 2 g per day)
Reserve for severe disease
Pediatric clinical features
Exudative pharyngitis prominent
May be indistinguishable from Streptococcal pharyngitis
Failure of beta-lactam therapy key diagnostic trigger
Lymphadenopathy may be pronounced
Risk of airway compromise from bulky nodes in small children
Neck ultrasound to assess extent
Special considerations
Doxycycline in children under 8 years
Generally avoided due to dental staining
May be used for life-threatening infection when other options unavailable
Immunocompromised children
Those on anti-TNF-alpha therapy or immunosuppression at high risk
Aggressive parenteral treatment and infectious disease involvement
Background
Epidemiology
Global distribution
Northern Hemisphere endemic zones
North America: south-central United States especially Missouri, Arkansas, Oklahoma
Europe: Scandinavia, Turkey, Kosovo, Balkan peninsula
Russia and Central Asia
Re-emerging zoonosis
Increased European incidence since 1990s
Waterborne outbreaks in Kosovo and Turkey
United States burden
Approximately 100 to 200 cases reported annually
Actual incidence likely higher due to underdiagnosis
MMWR 2001 to 2010: 1,208 reported cases
Seasonal pattern
Late summer to autumn peak in tick-borne transmission
Waterborne outbreaks variable across seasons
Oropharyngeal form prevalence
Predominant form in waterborne outbreaks
Accounts for majority of cluster cases
Associated with poor sanitation and water quality
Represents approximately 10 to 30% of all tularemia cases in endemic areas
Proportional increase during outbreaks
Pathophysiology
Organism characteristics
Francisella tularensis subspecies
Type A (tularensis): North America, higher virulence
Type B (holarctica): Europe and Asia, typically less severe
Extremely low infectious dose
Fewer than 10 organisms required for infection by inhalation
Ingestion requires higher inoculum (greater than 10 to the 8th organisms)
Environmental survival
Survives for weeks in cold water, mud, and animal carcasses
Explains waterborne outbreak potential
Mechanism of infection in oropharyngeal form
Entry via mucosal surfaces of oropharynx
Ingestion of contaminated water or undercooked meat
Local mucosal invasion and replication
Intracellular pathogen
Survives and replicates within macrophages and neutrophils
Inhibits phagosome-lysosome fusion
Lymphatic dissemination
Regional lymph node invasion and intense inflammatory reaction
Granuloma formation with central necrosis
Histologically identical to tuberculosis
Systemic dissemination pathway
Bacteremia from lymph node breakdown
Hematogenous spread to lung, liver, spleen
Secondary pneumonia most common systemic complication
Inflammatory response
Granulomatous inflammation in multiple organs
Suppuration and abscess formation in affected nodes
Therapeutic Considerations
Antibiotic mechanism and rationale
Aminoglycosides (gentamicin, streptomycin)
Intracellular penetration adequate for bactericidal effect
Historical standard of care with low relapse rates
Toxicity limits outpatient use
Fluoroquinolones (ciprofloxacin, levofloxacin)
Excellent intracellular penetration
2025 CDC designation as first-line for naturally acquired and outbreak management
Relapse rate 5 to 10%
Tetracyclines (doxycycline)
Bacteriostatic mechanism results in higher relapse rate 10 to 15%
Second-line to fluoroquinolones
Longer course required (14 to 21 days)
Treatment failure considerations
Overall treatment failure rate approximately 15%
Higher with delayed treatment beyond 2 to 3 weeks of illness
Fluoroquinolones associated with lower failure rates
Suppurative lymphadenopathy
Occurs in approximately 30% of patients with lymphadenopathy
May develop weeks after antibiotic initiation
Surgical drainage required in approximately 23% of these cases
Public health and bioterrorism context
Bioterrorism preparedness protocol
Stockpile of ciprofloxacin and doxycycline for mass prophylaxis
Rapid laboratory identification protocols at reference centers
No person-to-person transmission
Standard precautions adequate for hospital management
Contact tracing focuses on shared water or food source
Patient Discharge Instructions
copy discharge instructions
Tularemia (oropharyngeal) home care instructions
Take all antibiotics exactly as prescribed
Ciprofloxacin or doxycycline for the full course (10 to 21 days)
Do not stop early even if feeling better
Manage throat pain and fever
Acetaminophen or ibuprofen as directed
Soft diet or liquids until swallowing improves
Drink adequate fluids
At least 2 litres of water per day
Avoid dehydration from difficulty swallowing
Warning signs requiring immediate return to emergency department
Airway red flags
Difficulty breathing, stridor, or noisy breathing
Inability to swallow or drooling
Significant worsening of neck swelling
Infection worsening signs
Fever continuing after 72 hours of antibiotics
New confusion or unusual behaviour
New cough, chest pain, or shortness of breath
Antibiotic side effects
Severe tendon pain or rupture (ciprofloxacin)
Severe skin rash or photosensitivity reaction
Follow-up instructions
Recheck appointment in 5 to 7 days
Clinical response assessment
Convalescent blood tests at 2 to 4 weeks if diagnosis not confirmed
Lymph node monitoring
Swelling may take weeks to months to fully resolve
New fluctuance or fistula formation requires urgent reassessment
Prevention and exposure avoidance
Water safety
Avoid drinking untreated water from wells, springs, or streams
Boil or purify water in wilderness or endemic settings
Wild game handling and preparation
Cook rabbit and hare thoroughly to internal temperature above 74 C
Wear gloves when handling wild animals
Tick and insect protection
Use DEET repellent and permethrin-treated clothing in endemic areas
Daily tick checks after outdoor activity
No person-to-person spread
Household contacts not at risk unless shared exposure source
References
Guidelines and key sources
CDC and government guidelines
Nelson CA et al. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response — United States, 2025. MMWR Recomm Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/41026652
CDC Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers, Sixth Edition. 2022. https://www.cdc.gov/ticks/media/pdfs/2025/03/tickborne-diseases-manual-508.pdf
MMWR Tularemia — United States, 2001–2010. 2013. https://pubmed.ncbi.nlm.nih.gov/24280916
Key clinical reviews
Dennis DT et al. Tularemia as a Biological Weapon: Medical and Public Health Management. JAMA. 2001. https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.285.21.2763
Maurin M, Gyuranecz M. Tularaemia: Clinical Aspects in Europe. Lancet Infect Dis. 2016. https://pubmed.ncbi.nlm.nih.gov/26738841
Antonello RM et al. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. Eur J Intern Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40107886
Maurin M et al. Tularemia Treatment: Experimental and Clinical Data. Front Microbiol. 2023. https://pubmed.ncbi.nlm.nih.gov/38298538
Outbreak and clinical studies
Esmaeili P et al. Oropharyngeal Tularemia Outbreak Linked to Drinking Contaminated Tap Water in North-Western Iran. Diagn Microbiol Infect Dis. 2024. https://pubmed.ncbi.nlm.nih.gov/39146636
Weber IB et al. Clinical Recognition and Management of Tularemia in Missouri: A Retrospective Records Review of 121 Cases. Clin Infect Dis. 2012. https://pubmed.ncbi.nlm.nih.gov/22911645
Cakir Kiymaz Y et al. Evaluation of Clinical Characteristics, Laboratory Parameters, and Antibiotic Treatment in Patients Diagnosed With Tularemia. J Infect Chemother. 2025. https://pubmed.ncbi.nlm.nih.gov/39481537
Kossadoum RF et al. Tularemia in Pediatric Patients: A Case Series and Review of the Literature. Pediatr Infect Dis J. 2025. https://pubmed.ncbi.nlm.nih.gov/39312633
Diagnostic and microbiology references
Miller JM et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by IDSA and ASM. Clin Infect Dis. 2024. https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciae104
Ho BM et al. Wilderness Medical Society Clinical Practice Guidelines for Prevention and Management of Tick-Borne Illness. Wilderness Environ Med. 2021. https://journals.sagepub.com/doi/10.1016/j.wem.2021.09.001
ICD-10 coding
ICD-10 A21.2 Pulmonary tularemia
ICD-10 A21.3 Gastrointestinal tularemia
ICD-10 A21.8 Other forms of tularemia (including oropharyngeal)
ICD-10 A21.9 Tularemia unspecified
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.